The safety and efficacy of COVID-19 vaccines among lung transplant recipients

Phase 4

Recruiting

• Conditions: lung transplant recipients; lung transplant, solid organ transplant, COVID-19

• Registration Number: JPRN-jRCT1021210009
• Lead Sponsor: Okada Yoshinori

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Lung transplant recipients followed at Tohoku University Hospital who fulfilled the following criteria 1-5:
(1) 6 months after lung transplant
(2) two-time COVID-19 vaccination
(3) no history of COVID-19 infection
(4) 20 years old or above
(5) written informed consent obtained

Controls followed at Tohoku University Hospital or Tohoku Kosai Hospital who fulfilled the following criteria 1-4:
(1) no history of transplantation and immunosuppressive therapy
(2) two-time COVID-19 vaccination
(3) no history of COVID-19 infection
(4) 20 years old or above
(5) written informed consent obtained

Exclusion Criteria

(1) informed consent unobtained
(2) aged 19 years old or below

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of COVID-19 vaccine

Secondary Outcome Measures

Name	Time	Method
The safety of COVID-19 vaccine